In addition, even if TP53 mutations were absent at the time of diagnosis, DLBCL patients often presented with TP53 alterations when relapsing following R-CHOP therapy, which implied that TP53 is prone to mutations under immuno-chemotherapy [280]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.